Elizabeth L. Eberle

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Linda M. Rorick‐Kehn, Jeffrey M. Witkin, Michael A. Statnick et al. · Neuropharmacology · 2013 · 148 citations

Psychoactive Drug, Psychiatry, Functional Selectivity +7

Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing

Carrie K. Jones, Elizabeth L. Eberle, Stephen C. Peters et al. · Neuropharmacology · 2005 · 86 citations

Inflammation, Selective Group Ii, Health Sciences +14

Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats

Carrie K. Jones, Elizabeth L. Eberle, David B. Shaw et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 83 citations

Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats

Harlan E. Shannon, Elizabeth L. Eberle, Steven Peters · Neuropharmacology · 2005 · 82 citations

Anticonvulsant Drugs, Neurophysiology, Medicine +12

The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil

Matthew E. Barton, Elizabeth L. Eberle, Harlan E. Shannon · European Journal of Pharmacology · 2005 · 60 citations

Molecular Pharmacology, Health Sciences, Pain Medicine +10